Basic Information
Description
Biocytogen developed the immunodeficient B-NDG hSIRPA/hCD47 mice for in vivo efficacy evaluation of SIRPα antibodies, or in combination with other antibodies. These mice are in the highly immunodeficient B-NDG mouse background (completely lacking mature T, B and NK cells and were deficient in cytokine signaling) with SIRPα and CD47 IgV domain replaced by its human counterpart. In homozygous B-NDG hSIRPA/hCD47 mice, mouse SIRPα and CD47 were absent and only human protein expression was detected. B-NDG hSIRPA/hCD47 mice paired with genetically modified Raji-luc cancer cells were used to evaluate the efficacy of combination antibodies targeting SIRPα and other targets. The results showed that the combination of antibodies could effectively control tumor growth. B-NDG hSIRPA/hCD47 mice are promising models for preclinical in vivo pharmacodynamic assessment of SIRPα antibodies in combination with other targets or related bispecific antibodies.
